Safety and Effectiveness Analysis of Kivexa<sup>®</sup>(lamivudine/abacavir sulfate) in Human Immunodeficiency Virus Infected Korean Patients

20194 citationsJournal Articlegold Open Access

Authors

H. Ann · Yonsei University

Yil-Seob Lee · The Genetics Society of Korea

Kim Ys · Chungnam National University

Sook‐In Jung · Chonnam National University Hospital

Sun Hee Lee · Pusan National University

Chang‐Seop Lee · Jeonbuk National University

Jin Soo Lee ·

Abstract

The post-marketing surveillance showed the safety of Kivexa in HIV-1 patients in Korea. Ischemic cardiovascular events and hypersensitivity associated with Kivexa were few. There was no significant new safety information. This data may be helpful in implementing Kivexa and lamivudine/abacavir sulfate containing drugs in Korea.

Topics & Keywords

HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions Pneumocystis jirovecii pneumonia detection and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Infection and Chemotherapy

Volume 51, Issue 2, pp. 150-150

DOI: 10.3947/ic.2019.51.2.150

Field-Weighted Citation Impact: 0.29